Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives.
Iman Abou DalleRémy DuléryNour MoukalledLaure RicardNicolas StockerJean El-CheikhMohamad MohtyAli BazarbachiPublished in: Blood cancer journal (2024)
Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.
Keyphrases
- stem cell transplantation
- end stage renal disease
- high dose
- diffuse large b cell lymphoma
- electronic health record
- chronic kidney disease
- ejection fraction
- newly diagnosed
- big data
- acute lymphoblastic leukemia
- cell therapy
- prognostic factors
- acute myeloid leukemia
- bone marrow
- peritoneal dialysis
- stem cells
- multiple myeloma
- machine learning
- mesenchymal stem cells
- radiation therapy
- patient reported outcomes
- artificial intelligence
- deep learning
- combination therapy
- replacement therapy
- data analysis